JANUVIA
Home
Clinical Experience
Head-to-Head vs Sulfonylurea
Initial Combination Therapy
As Add-on Therapy
DPP-4 Inhibition
Clinical Studies
Dosing
Mechanism of Action
Formulary Coverage
Hypothetical Patient Profiles
Selected Important Safety Information
Request More Information
Patient Web Site
Contact Us
Selected Important Risk Information
There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.
Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.
Important Information
JANUVIA® (sitagliptin) tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.
Before prescribing JANUVIA® (sitagliptin) tablets, please read the Prescribing Information. The Medication Guide also is available.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
DIAB-1050515-0002 12/12
PRIVACY POLICY